21.3 C
New York
Friday, October 7, 2022

SurvivorNet Announces SurvivorNetTV's Special New Programming Slate Marking Breast Cancer Awareness Month – Yahoo Finance

NEW YORK, Sept. 20, 2022 /PRNewswire/ — Throughout the month of October, health information company SurvivorNet’s unique streaming platform SurvivorNetTV will broadcast a specialized slate of award-winning films, original videos and shoutouts from the cancer survivor community, all designed to provide support for women experiencing breast cancer.
This first-time-ever initiative, part of SurvivorNet’s robust, year-round effort to provide information, support and comfort to breast cancer patients, is designed to coincide with Breast Cancer Awareness Month. It aims both to help educate women about the disease and to create an emphatic call to action for preventative testing.
Signature programming includes the Emmy Award-winning series The Big C, which stars Laura Linney and beautifully uses comedy to chart the main character’s personal battle with cancer. Viewers can also tune into SN&You, the channel’s original series covering everything from the latest cancer-focused science to cannabis to sex after cancer. Celebrity members of the cancer community such as Joan Lunden, Giuliana Rancic and Amy Robach can also be found on the channel sharing wisdom and inspiration.

Specialized breast cancer programming planned for the month includes award-winning nonfiction films like Jim Allison: Breakthrough, the groundbreaking documentary on the Nobel Prize-winning scientist behind game-changing discoveries in immunotherapy. Uplifting features include The C Word, which examines the role of diet and exercise in helping us stay healthy. Also available is short-form inspirational programming such as The Power Of Mindset series. These five films serve as beautiful reminders that the way we think can prove to be a powerful tool when it comes to maintaining balance and happiness, even while living with cancer.
Now streaming to millions of monthly active users across linear and connected TV, accessible via app stores and the LG Smart TV dashboards, SurvivorNetTV is the first channel for cancer survivors. It features 24-hour programming that shares information, hope and inspiration with the millions-strong cancer community.
Across Breast Cancer Awareness Month and beyond, SurvivorNet offers important, expert-driven information for decision-making as well support. SurvivorNet is also deeply invested in educating women and their doctors about some of the remarkable new clinical advances in preventing, treating and living with breast cancer.
About SurvivorNet
SurvivorNet is the country’s leading platform for cancer information, serving 2.5 million people per month who are looking for help making better decisions about their care. The platform was built in collaboration with leading comprehensive cancer centers and features top physicians delivering highly detailed information about specific cancers. SurvivorNet also has produced thousands of stories intended to provide hope and inspiration for patients.
Steve Alperin is the founder and CEO of SurvivorNet.
For publicity: business@survivornet.com
For sales & partnership: Paul.McKenna@survivornet.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/survivornet-announces-survivornettvs-special-new-programming-slate-marking-breast-cancer-awareness-month-301627744.html
SOURCE SurvivorNet
Get more savings at your fingertips with these Best Buy deals on Beats headphones, Hisense TVs and Chefman air fryers.
Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.
Shares of Eli Lilly & Co. Inc. gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company's newly approved Type 2 diabetes drug, could be "the biggest drug ever." UBS analysts predict peak sales of $25 billion if the therapy is also approved as a treatment for weight management in people with obesity. "Tirzepatide's robust efficacy in both obesity and [Type 2 diabetes] should drive sales into a range that we believe could see this
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
The bear market hasn't dragged down Axsome Therapeutics (NASDAQ: AXSM). The biotech company specializes in treating central nervous system conditions. And it's been on a roll with good news — and share performance — in recent weeks.
‘We were dying on the inside,’ actor said
Recent challenges aside, the company's service is the default choice for many consumers when it comes to watching TV.
Clovis Oncology Inc (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd signed a clinical supply agreement that provides Clovis Oncology with Isotopia's lutetium-177 (177Lu) n.c.a. for use in the clinical development of FAP-2286, Clovis' fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is currently being investigated in the Phase 1/2 LuMIERE study for patients with advanced solid tumors. The agreement covers an initial period of two years. Further details of the agreem
A potentially disruptive business model is finding its legs in the post-pandemic healthcare landscape.
The company’s last attempt to target the devastating disease flopped. Results from a key trial of Biogen and Eisai’s new drug, lecanemab, are coming soon—and have huge implications.
Khosla Ventures is throwing its weight behind a new CRISPR/Cas13 startup, and Sesen Bio, formerly Eleven Biotherapeutics, is finally shutting down after 14 years.
‘Real Time with Bill Maher’ features guests to discuss current events in politics and media
After falling short on two previous attempts, a drugmaker in Research Triangle Park has secured regulatory approval for its lead product and is now set to see major dollars to support commercialization.
Salesforce is building software for the future of work, but can it push a cultural shift beyond the Great Resignation?
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
To avert a collision of patents and safety regulations, the Supreme Court must ensure that a damaging ruling is quickly undone.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infection. The trial did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of COVID-19 at day 14 of Tempol versus placebo. Last year, the company started dosing in the Phase 2/3 trial for Tempol, which was designed to enroll 248 patients. Th
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
(Bloomberg) — Scion Asset Management founder Michael Burry has taken another veiled swipe at Tesla Inc., after one of its batteries was blamed for shutting a stretch of an iconic California highway.Most Read from BloombergPutin Mobilizes More Troops, Wields Ukraine Nuclear ThreatHome-Flipper Opendoor Hit With Losses in Echo of Zillow CollapseTycoon's Wild $3 Billion Gamble on ‘China's LVMH’ Crashes‘Mute Your Phones’: Trump Special Master Hearing Descends Into ChaosFed Set to Reveal ‘Pain’ Comin
King Charles is reportedly planning to cut Prince Harry, as well as Prince Andrew and Princess Beatrice, as official stand-ins should he be indisposed.


Related Articles


Please enter your comment!
Please enter your name here

Latest Articles